Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.42 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.39 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.38 |
| ▸ | DUT | P33316 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9909473 | 1.00 | CYP3A4 (0.69) | CYP3A4CYP2C9P2RY2P2RY6P2RY14 | |
| SCHEMBL9909521 | 1.00 | CYP3A4 (0.69) | CYP3A4CYP2C9P2RY2P2RY6P2RY14 | |
| SCHEMBL9104825 | 1.00 | CYP3A4 (0.69) | CYP3A4CYP2C9P2RY2P2RY6P2RY14 | |
| SCHEMBL9106317 | 1.00 | CYP3A4 (0.69) | CYP3A4CYP2C9P2RY2P2RY6P2RY14 | |
| SCHEMBL9104831 | 1.00 | CYP3A4 (0.69) | CYP3A4CYP2C9P2RY2P2RY6P2RY14 | |
| SCHEMBL9102628 | 0.97 | CYP3A4 (0.71) | CYP3A4CYP2C9P2RY2P2RY6P2RY14 | |
| SCHEMBL10239235 | 0.97 | CYP3A4 (0.71) | CYP3A4CYP2C9P2RY2P2RY6P2RY14 | |
| SCHEMBL9103804 | 0.97 | CYP3A4 (0.71) | CYP3A4CYP2C9P2RY2P2RY6P2RY14 | |
| SCHEMBL9909467 | 0.97 | CYP3A4 (0.71) | CYP3A4CYP2C9P2RY2P2RY6P2RY14 | |
| SCHEMBL9102634 | 0.97 | CYP3A4 (0.71) | CYP3A4CYP2C9P2RY2P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3042910-B1 | 2'-SPIRO-NUCLEOSIDES FOR USE IN THE THERAPY OF HEPATITIS C | GILEAD PHARMASSET LLC (US) | 2019-01-09 | — | — | EP | disclosed |
| US-9394331-B2 | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections | GILEAD PHARMASSET LLC (US) | 2016-07-19 | — | — | US | disclosed |
| US-8841275-B2 | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections | GILEAD PHARMASSET LLC (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2646453-A1 | COMPOUNDS | Gilead Pharmasset LLC (US) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012075140-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142626-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142626-A1 | COMPOUNDS | HAVCR2, EIF2AK2, NTPCR | CYP3A4 835/4885CYP2C9 1676/4885P2RY2 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.